A chimeric antigen receptor targeting CD7 protein and its applications
By designing a chimeric antigen receptor targeting the CD7 protein and optimizing the activation and killing functions of CAR-T cells, the problems of immunodeficiency and mutual killing in T-cell tumor therapy have been solved, achieving highly efficient killing and improved safety for T-ALL and lymphoma.
Patent Information
- Application Number
- CN202210267342.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-03-17
- Publication Date
- 2026-11-17
- Estimated Expiration
- 2042-03-17
AI Technical Summary
Current CAR-T cell therapies are not very effective in treating T-cell tumors such as T-ALL and lymphoma, and there are problems such as immunodeficiency and mutual killing between CAR-T cells, resulting in a lack of safe and effective treatment options.
We designed a chimeric antigen receptor targeting the CD7 protein, including its extracellular, transmembrane, and intracellular domains. We then used nanobodies targeting the CD7 protein and co-stimulatory signal transduction regions to optimize the activation and killing functions of CAR-T cells and improved their safety through ubiquitination deletion modification.
It improved the killing efficiency of CAR-T cells against T-cell tumors, reduced the killing of normal T cells, and reduced the mutual killing among CAR-T cells, thus significantly improving tumor killing function and survival rate.
Smart Images

Figure CN116789844B_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of chimeric antigen receptors, and more specifically to a chimeric antigen receptor that targets the CD7 protein and its uses. Background Technology
[0002] CAR stands for chimeric antigen receptor. Its main components include: a single-chain antibody fragment (scFv) that can recognize and bind to specific tumor antigens, enabling precise identification and "targeted attack" of tumor cells; an intracellular domain of the ζ chain of the T cell receptor (TCR), which can effectively activate T cells after the scFv recognizes the tumor antigen. The activated T cells can secrete a large number of cytokines, rapidly proliferate, and effectively kill tumor cells. They also recruit other immune cells through secreted inflammatory factors, further enhancing the killing and phagocytosis of tumor cells; on this basis, coupling one or two intracellular signaling domains of T cell co-stimulatory molecules can enhance the ability of CAR to activate T cells and improve the function of CAR-T cells.
[0003] T cells expressing CARs that target specific tumor antigens are called CAR-T cells. CAR-T therapy is a cell-transfer immunotherapy that involves infusing CAR-T cells into cancer patients to precisely target tumor cells. In 2017, the US FDA approved two commercially available CAR-T products targeting the CD19 antigen for the treatment of relapsed / refractory B-cell leukemia and lymphoma, demonstrating significant efficacy. However, there are currently no mature commercially available CAR-T products specifically targeting T-cell tumors such as lymphoma and leukemia.
[0004] T-cell acute lymphoblastic leukemia (T-ALL) is a highly aggressive malignant hematological malignancy characterized by rapid progression, high relapse rate, and low median survival. Effective treatments for relapsed / refractory T-cell lymphoma are limited; for example, allogeneic stem cell transplantation is difficult and expensive. Although the U.S. Food and Drug Administration (FDA) has approved the chemotherapy drug nerabine for the treatment of T-ALL patients who have failed at least two treatment regimens or have relapsed, nerabine is not yet available in my country, and according to FDA clinical research reports, its complete remission rate for T-ALL is less than 30%. Therefore, the treatment of T-cell tumors, especially relapsed / refractory T-ALL and T-cell lymphoma, is challenging, and there is an urgent need to develop safer and more effective treatment options. Summary of the Invention
[0005] In view of the shortcomings of the prior art described above, the object of the present invention is to provide a chimeric antigen receptor targeting the CD7 protein and its uses.
[0006] To achieve the above and other related objectives, a first aspect of the present invention provides a chimeric antigen receptor targeting the CD7 protein, comprising:
[0007] The extracellular domain, transmembrane domain, and intracellular domain are connected sequentially.
[0008] The extracellular domain includes an antigen recognition region, which is a nanobody targeting the CD7 protein; the amino acid sequence of the CD7 protein-targeting nanobody is shown in any one of SEQ ID NO: 1-SEQ ID NO: 3. A second aspect of the present invention provides a polynucleotide sequence, the polynucleotide sequence being selected from:
[0009] (1) A multinucleotide sequence encoding the aforementioned chimeric antigen receptor targeting the CD7 protein; and / or
[0010] (2)(1) The complementary sequence of the polynucleotide sequence.
[0011] A third aspect of the present invention provides a nucleic acid construct containing the aforementioned polynucleotide sequence; preferably, the nucleic acid construct is a vector; more preferably, the nucleic acid construct is a lentiviral vector containing a replication start site, a 3'LTR, a 5'LTR, and the aforementioned polynucleotide sequence.
[0012] A fourth aspect of the present invention provides a lentivirus containing the aforementioned nucleic acid construct.
[0013] A fifth aspect of the present invention provides a method for activating T cells in vitro, the method comprising the step of infecting the T cells with the aforementioned lentivirus.
[0014] The sixth aspect of the present invention provides a genetically modified T cell or a pharmaceutical composition containing the genetically modified T cell, characterized in that the cell contains the aforementioned polynucleotide sequence, or contains the aforementioned nucleic acid construct, or is infected with the aforementioned lentivirus, or is prepared by the aforementioned method.
[0015] The seventh aspect of the present invention provides the use of the aforementioned chimeric antigen receptor, polynucleotide sequence, nucleic acid construct or lentivirus in the preparation of T cell activators and / or T cell degradation inhibitors.
[0016] The eighth aspect of the present invention provides the use of the aforementioned chimeric antigen receptor, polynucleotide sequence, nucleic acid construct, lentivirus, or genetically modified T cell in any one or more of the following uses: (1) preparing a tumor therapeutic drug; (2) preparing an agent to improve the killing efficiency against tumors; (3) preparing an agent to maintain the proliferative capacity of T cells; (4) preparing an agent to inhibit tumor development; preferably, the tumor is selected from one or more of leukemia or lymphoma; more preferably, the tumor is selected from T-cell lymphoma, T-cell type acute lymphoblastic leukemia, B-cell type acute lymphoblastic leukemia, chronic lymphocytic leukemia, hairy cell leukemia, and acute myeloid leukemia.
[0017] As described above, the chimeric antigen receptor targeting the CD7 protein and its use in this invention have the following beneficial effects:
[0018] This invention provides a chimeric antigen receptor targeting the CD7 protein and modifies it by removing ubiquitination. Its sustained proliferation capacity and killing function under continuous in vitro stimulation were tested on human primary T cells, and its tumor-killing function in tumor-bearing mice was also tested. Compared with CAR sequences reported in the literature, the nanobody CAR of this invention exhibits superior performance. Attached Figure Description
[0019] Figure 1 The specific recognition of human CD7 protein by positive monoclonal antibodies obtained from phage display library screening was verified by enzyme-linked immunosorbent assay (ELISA).
[0020] Figure 2 Flow cytometry was used to detect CAR expression on the cell membrane and the autoactivation level of CAR-T cells in resting state. The detection level of Myc tag coupled to the CARN terminus was used to indicate the CAR expression on the cell membrane, and the T cell activation marker protein CD69 was used to indicate the autoactivation level of CAR-T cells. (a. Expression level of some nanobody CAR cells on the cell surface; b. Background autoactivation level of some nanobody CAR cells).
[0021] Figure 3 Flow cytometry was used to detect CAR expression on the cell membrane, as well as its basal autoactivation level and the cell exhaustion level caused by this autoactivation signal under resting conditions. The levels of T cell activation indicator proteins CD69 and ICOS were used to reflect the autoactivation level of CAR-T cells, while the levels of T cell exhaustion indicator proteins PD1, LAG3, and TIM3 were used to reflect the exhaustion level of CAR-T cells. (a. Flow cytometry detection of basal autoactivation level of CAR-T cells; b. Flow cytometry detection of CAR-T cell exhaustion level under resting conditions).
[0022] Figure 4 CAR activation levels were detected by flow cytometry. (a. CD69 expression levels in T cell lines expressing three nanobody CARs after stimulation with target cells; b. CD69 expression levels in T cell lines expressing three nanobody CARs after stimulation with non-target cells).
[0023] Figure 5 Detection of the killing function of different nanobodies CAR and PA7-13 on CD7-positive target cells. The fluorescence intensity produced by the consumption of the substrate luciferin by firefly luciferase expressed by the target cells reflects the killing ability of CAR-T cells on target cells.
[0024] Figure 6 Detection of the killing function of primary T cells expressing E7-CAR against tumor target cells and non-target cells. E7 nanobody CAR was expressed on human primary T cells with CD7 protein knockout, and its killing function against target cells and non-target cells was tested.
[0025] Figure 7 The cytokine secretion level of E7 CAR-T cells under target cell stimulation was detected by ELISA.
[0026] Figure 8 This study assesses the proliferation of wild-type E7 CAR-T cells and E7 CAR-T cells lacking ubiquitination modification in vitro under continuous stimulation by target cells. (Detection of the sustained proliferation capacity of wild-type and ubiquitination-deficient E7-CAR T cells under in vitro antigen stimulation).
[0027] Figure 9 This study is an in vivo tumor-killing experiment in tumor-bearing mice, verifying that ubiquitination-deficient E7 CAR-T cells can effectively kill tumor cells in tumor-bearing mice and significantly improve the survival time of the mice. (a. Tumor-killing function of ubiquitination-deficient E7 CAR-T cells in tumor-bearing mice; b. Survival analysis of tumor-bearing mice after cell therapy) Detailed Implementation
[0028] The following specific examples illustrate the implementation of the present invention. Those skilled in the art can easily understand other advantages and effects of the present invention from the content disclosed in this specification. The present invention can also be implemented or applied through other different specific embodiments, and various details in this specification can also be modified or changed based on different viewpoints and applications without departing from the spirit of the present invention.
[0029] Before further describing specific embodiments of the present invention, it should be understood that the scope of protection of the present invention is not limited to the specific embodiments described below; it should also be understood that the terminology used in the embodiments of the present invention is for describing specific embodiments and not for limiting the scope of protection of the present invention; in the specification and claims of the present invention, unless otherwise expressly stated in the text, the singular forms "a", "an" and "this" include the plural forms.
[0030] When numerical ranges are given in the embodiments, it should be understood that, unless otherwise stated in the present invention, both endpoints of each numerical range and any value between the two endpoints may be selected. Unless otherwise defined, all technical and scientific terms used in this invention have the same meaning as commonly understood by one of ordinary skill in the art. In addition to the specific methods, apparatus, and materials used in the embodiments, based on the knowledge of the prior art possessed by one of ordinary skill in the art and the description of this invention, any prior art methods, apparatus, and materials similar to or equivalent to those described, apparatus, and materials in the embodiments of this invention may be used to implement the present invention.
[0031] Unless otherwise stated, the experimental methods, detection methods, and preparation methods disclosed in this invention all employ conventional techniques in molecular biology, biochemistry, chromatin structure and analysis, analytical chemistry, cell culture, recombinant DNA technology, and related fields.
[0032] Based on the excellent efficacy of CAR-T cell therapy in B-cell lymphoma, we hope to develop a safer and more effective CAR-T product for T-cell tumors, including T-ALL and lymphoma, bringing new treatment opportunities to a wider range of patients.
[0033] CD7 is a highly specific target on the surface of T cells and is expressed early in T cell differentiation. Therefore, it may be expressed in various tumors, including blastoblastic T-cell tumors (T-ALL / lymphoblastic lymphoma), mature T-cell tumors (peripheral T-cell lymphoma, anaplastic large cell lymphoma, etc.), NK / T-cell tumors, and acute myeloid leukemia (AML). Thus, CD7 can serve as a tumor-associated antigen (TAA) for hematologic malignancies, especially T-cell tumors, including T-cell lymphoma and leukemia [4-8]. However, using this indicative protein co-expressed by T cells as a target for CAR-T cell killing has the following two main problems: 1. The powerful killing function of CAR-T cells may kill a large number of normal T cells that also express CD7 protein while killing CD7-positive tumor cells, leading to serious immunodeficiency problems. However, current research indicates that approximately 10% of normal T cells in the human body are CD7 negative and possess normal function. These normal T cells, which cannot be killed by CD7-targeted CAR-T cells, can play a role in cellular immunity to some extent. Furthermore, some have proposed that constructing and reinfusing CD7-deficient hematopoietic stem cells could be used to restore T and NK cells after CD7-targeted CAR-T cell therapy. 2. The problem of "mutual killing" among CAR-T cells. Because CAR-T cells are also T cells and express CD7, they can be killed as target cells for other CAR-T cells, leading to "mutual killing" among CAR-T cells. Therefore, when constructing CAR-T cells, it is necessary to remove the CD7 protein expressed on the surface of T cells in a certain way (gene editing, protein retention within the cell, etc.).
[0034] In summary, CD7 is a highly specific tumor-associated target for T-cell tumors, including lymphoma and leukemia. Furthermore, existing technologies can overcome the difficulties in its preparation and application, making it a relatively ideal target for CAR-T cell therapy of T-cell lymphoma / leukemia.
[0035] This invention utilizes phage display screening technology to screen for multiple nanobodies that specifically recognize human CD7 protein, and constructs them into chimeric antigen receptors (CARs). These CARs are then expressed in CD7-knockout human junket T cell lines, and their specific recognition of the CD7 antigen and the resulting CAR-T cell activation levels are detected. The baseline expression levels of various activation indicators of each CAR-T cell under resting conditions are compared to confirm their baseline autoactivation levels. A CAR structural sequence (E7) with high specificity, high response to CD7 antigen stimulation, and low baseline autoactivation level is selected and expressed in human primary T cells for in vitro cellular level and in vivo functional validation in tumor-bearing mice.
[0036] Based on our existing patent (201910302508X), we modified the sequence to remove ubiquitin and tested its continuous proliferation capacity and killing function in human primary T cells under continuous in vitro stimulation. We also tested its tumor killing function in tumor-bearing mice. Compared with the CAR sequences reported in the literature, our nanobody CAR has a more outstanding effect.
[0037] The chimeric antigen receptor targeting the CD7 protein described in this invention comprises:
[0038] The extracellular domain, transmembrane domain, and intracellular domain are connected sequentially.
[0039] The extracellular domain includes an antigen recognition region, which is a nanobody targeting the CD7 protein; the amino acid sequence of the nanobody targeting the CD7 protein is shown in any one of SEQ ID NO: 1-SEQ ID NO: 3;
[0040] D2(SEQ ID NO: 1):
[0041] EVQLVESGGGLVQPGGSLRLSCAASGRTFSPYVMGWFRQAPGKGRELVADISSSGGSTYYPDSVEGRFTISRDNAKRMVYLQMNSLRAEDTAVYYCAAKPWPPFGPYTYAYNYWGQGTQVTVSSGGS
[0042] D4(SEQ ID NO: 2:
[0043] EVQLVESGGGLVQPGGSLRLSCAASGITFSTYNMGWFRQAPGKGRELVAAISRTGGSTYYPDSVEGRFTISRDNAKRMVYLQMNSLRAEDTAVYYCAASLYPDGYLSIYSYNYWGQGTQVTVSSGGS
[0044] E7 (SEQ ID NO: 3):
[0045] EVQLVESGGGLVQPGGSLRLSCAASGRTFSTNRMGWFRQAPGKGRELVAAINSRDSRTWYPDSVEGRFTISRDNAKRMVYLQMNSLRAEDTAVYYCAAGGEIYSLGDDWFGWGPYDYWGQGTQVTVSSGGS
[0046] The intracellular domain includes a co-stimulatory signal transduction region and a CD3ζ intracellular region connected in sequence, forming a co-stimulatory signal transduction region-CD3ζ intracellular region;
[0047] In one embodiment, the co-stimulatory signal transduction region is selected from the intracellular regions of CD27, CD28, CD134, 41BB, or ICOS.
[0048] Preferably, the co-stimulatory signal transduction region is selected from the 41BB intracellular region.
[0049] In one embodiment, the amino acid sequence of the 41BB intracellular region is as shown in SEQ ID NO: 4 (wild type). Specifically: KRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL
[0050] In one embodiment, the amino acid sequence of the CD3ζ intracellular region is as shown in SEQ ID NO: 5 (wild type). Specifically:
[0051] RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPQRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR
[0052] In one embodiment, the co-stimulatory signal transduction region - CD3ζ intracellular region is a polypeptide formed by mutating lysine to arginine in the wild-type co-stimulatory signal transduction region - CD3ζ intracellular region.
[0053] In one embodiment, the amino acid sequence of the co-stimulatory signal transduction region - CD3ζ intracellular region is as shown in SEQ ID NO: 6 (41BB-CD3ζ wild type) or SEQ ID NO: 7 (ubiquitination-deleted type). Specifically:
[0054] KRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPQRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR. (SEQ ID NO: 6)
[0055] RRGRRRLLYIFRQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVRFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDRRRGRDPEMGGRPQRRRNPQEGLYNELQRDRMAEAYSEIGMRGERRRGRGHDGLYQGLSTATRDTYDALHMQALPPR. (SEQ ID NO: 7)
[0056] Furthermore, the extracellular domain also includes a signal peptide and / or a hinge region, forming a sequentially connected signal peptide-antigen recognition region-hinge region.
[0057] Preferably, the signal peptide is selected from the CD8α signal peptide and / or the hinge region is selected from the hinge region of CD8α.
[0058] Optionally, the extracellular domain further includes a tag. A signal peptide-tag-antigen recognition region-hinge region is formed in sequence. The tag can be a myc tag. The amino acid sequence of the myc tag is shown in SEQ ID NO: 8.
[0059] Specifically: EQKLISEEDL. (SEQ ID NO: 8)
[0060] In one embodiment, the amino acid sequence of the CD8α signal peptide is shown in SEQ ID NO: 9. Specifically:
[0061] MALPVTALLLPLALLLHAARP. (SEQ ID NO: 9)
[0062] In one embodiment, the amino acid sequence of the hinge region of CD8α is shown in SEQ ID NO: 10. Specifically:
[0063] TTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACD. (SEQ ID NO: 10)
[0064] The transmembrane domain is selected from the transmembrane regions of CD4, CD8α, OX40, or H2-Kb. Preferably, it is selected from the transmembrane region of CD8α.
[0065] In one embodiment, the amino acid sequence of the transmembrane region of CD8α is shown in SEQ ID NO: 11. Specifically:
[0066] IYIWAPLAGTCGVLLLSLVIT. (SEQ ID NO: 11)
[0067] In one embodiment, the amino acid sequence of the chimeric antigen receptor is as shown in any of SEQ ID NO: 12-17. Specifically:
[0068] MALPVTALLLPLALLLHAARPEQKLISEEDLEVQLVESGGGLVQPGGSLRLSCAASGRTFSPYVMGWFRQAPGKGRELVADISSSGGSTYYPDSVEGRFTISRDNAKRMVYLQMNSLRAEDTAVYYCAAKPWPPFGPYTYAYNYWGQGTQVTVSSGGSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAV HTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPQRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR(SEQ ID NO: 12, D2 CAR)
[0069] MALPVTALLLPLALLLHAARPEQKLISEEDLEVQLVESGGGLVQPGGSLRLSCAASGITFSTYNMGWFRQAPGKGRELVAAISRTGGSTYYPDSVEGRFTISRDNAKRMVYLQMNSLRAEDTAVYYCAASLYPDGYLSIYSYNYWGQGTQVTVSSGGSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPQRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR(SEQ ID NO:13,D4 CAR)
[0070] MALPVTALLLPLALLLHAARPEQKLISEEDLEVQLVESGGGLVQPGGSLRLSCAASGRTFSTNRMGWFRQAPGKGRELVAAINSRDSRTWYPDSVEGRFTISRDNAKRMVYLQMNSLRAEDTAVYYCAAGGEIYSLGDDWFGWGPYDYWGQGTQVTVSSGGSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPQRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR(SEQ ID NO:14,E7 CAR)
[0071] MALPVTALLLPLALLLHAARPEQKLISEEDLEVQLVESGGGLVQPGGSLRLSCAASGRTFSTNRMGWFRQAPGKGRELVAAINSRDSRTWYPDSVEGRFTISRDNAKRMVYLQMNSLRAEDTAVYYCAAGGEIYSLGDDWFGWGPYDYWGQGTQVTVSSGGSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCRRGRRRLLYIFRQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVRFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDRRRGRDPEMGGRPQRRRNPQEGLYNELQRDRMAEAYSEIGMRGERRRGRGHDGLYQGLSTATRDTYDALHMQALPPR(SEQ ID NO: 15, E7 ubiquitination-deficient CAR)
[0072] MALPVTALLLPLALLLHAARPEQKLISEEDLEVQLVESGGGLVQPGGSLRLSCAASGRTFSPYVMGWFRQAPGKGRELVADISSSGGSTYYPDSVEGRFTISRDNAKRMVYLQMNSLRAEDTAVYYCAAKPWPPFGPYTYAYNYWGQGTQVTVSSGGSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCRRGRRRLLYIFRQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVRFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDRRRGRDPEMGGRPQRRRNPQEGLYNELQRDRMAEAYSEIGMRGERRRGRGHDGLYQGLSTATRDTYDALHMQALPPR(SEQ ID NO: 16, D2 ubiquitination-deficient CAR)
[0073] MALPVTALLLPLALLLHAARPEQKLISEEDLEVQLVESGGGLVQPGGSLRLSCAASGITFSTYNMGWFRQAPGKGRELVAAISRTGGSTYYPDSVEGRFTISRDNAKRMVYLQMNSLRAEDTAVYYCAASLYPDGYLSIYSYNYWGQGTQVTVSSGGSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAV HTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCRRGRRRLLYIFRQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVRFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDRRRGRDPEMGGRPQRRRNPQEGLYNELQRDRMAEAYSEIGMRGEERRRGRGHDGLYQGLSTATRDTYDALHMQALPPR(SEQ ID NO: 17, D4 ubiquitination-deficient CAR)
[0074] The various portions forming the chimeric antigen receptor of the present invention can be directly linked to each other or linked via adapter sequences. The adapter sequence can be a known antibody-compatible adapter sequence, such as a G and S-containing adapter sequence. Typically, the adapter contains one or more repeating motifs. For example, the motif can be GGGS, GGGGS, SSSSG, GSGSA, and GGSGG. Preferably, the motifs are adjacent in the adapter sequence, with no inserted amino acid residues between the repeats. The adapter sequence can consist of 1, 2, 3, 4, or 5 repeating motifs. The length of the adapter can be 3 to 25 amino acid residues, for example, 3 to 15, 5 to 15, or 10 to 20 amino acid residues. In some embodiments, the adapter sequence is a polyglycine adapter sequence. The number of glycine residues in the adapter sequence is not particularly limited, typically 2 to 20, for example, 2 to 15, 2 to 10, or 2 to 8. Besides glycine and serine, the linker may also contain other known amino acid residues, such as alanine (A), leucine (L), threonine (T), glutamic acid (E), phenylalanine (F), arginine (R), glutamine (Q), etc.
[0075] It should be understood that in gene cloning, it is often necessary to design suitable restriction enzyme sites, which inevitably introduces one or more irrelevant residues at the end of the expressed amino acid sequence, without affecting the activity of the target sequence. To construct fusion proteins, promote the expression of recombinant proteins, obtain recombinant proteins that are automatically secreted outside the host cell, or facilitate the purification of recombinant proteins, it is often necessary to add some amino acids to the N-terminus, C-terminus, or other suitable regions within the recombinant protein, such as, but not limited to, suitable adaptor peptides, signal peptides, leader peptides, and terminal extensions. Therefore, the amino or carboxyl terminus of the fusion protein of the present invention (i.e., the CAR) may also contain one or more polypeptide fragments as protein tags. Any suitable tag can be used herein. For example, the tags may be FLAG, HA, HA1, c-Myc, Poly-His, Poly-Arg, Strep-TagII, AU1, EE, T7, 4A6, ε, B, gE, and Ty1. These tags can be used for protein purification.
[0076] The polynucleotide sequence provided by this invention is selected from:
[0077] (1) A multinucleotide sequence encoding the aforementioned chimeric antigen receptor; and / or
[0078] (2)(1) The complementary sequence of the polynucleotide sequence.
[0079] Preferably, the polynucleotide sequence is as shown in any one of SEQ ID NO: 18-23. Specifically:
[0080]
[0081]
[0082]
[0083]
[0084]
[0085]
[0086] The polynucleotide sequences of this invention can be in DNA or RNA form. DNA form includes cDNA, genomic DNA, or artificially synthesized DNA. DNA can be single-stranded or double-stranded. DNA can be a coding strand or a non-coding strand. This invention also includes degenerate variants of polynucleotide sequences encoding fusion proteins, i.e., nucleotide sequences encoding the same amino acid sequence but with different nucleotide sequences.
[0087] The polynucleotide sequences described herein can typically be obtained using PCR amplification. Specifically, primers can be designed based on the nucleotide sequences disclosed herein, especially the open reading frame sequences, and the relevant sequences can be amplified using commercially available cDNA libraries or cDNA libraries prepared according to conventional methods known to those skilled in the art. When the sequences are long, it is often necessary to perform two or more PCR amplifications, and then splice the fragments amplified from each amplification in the correct order.
[0088] The nucleic acid constructs provided by this invention contain the aforementioned polynucleotide sequences.
[0089] The nucleic acid construct further includes one or more regulatory sequences operatively linked to the aforementioned polynucleotide sequence. The coding sequence of the CAR described in this invention can be manipulated in various ways to ensure protein expression. The nucleic acid construct can be manipulated before insertion into the expression vector, depending on the specific expression vector or requirements. Techniques for altering polynucleotide sequences using recombinant DNA methods are known in the art.
[0090] The regulatory sequence can be a suitable promoter sequence. The promoter sequence is typically operatively linked to the coding sequence of the protein to be expressed. The promoter can be any nucleotide sequence that exhibits transcriptional activity in the selected host cell, including mutant, truncated, and heterozygous promoters, and can be obtained from a gene encoding an extracellular or intracellular polypeptide that is homologous or heterologous to that of the host cell.
[0091] The regulatory sequence can also be a suitable transcription terminator sequence, a sequence recognized by the host cell to terminate transcription. The terminator sequence is operatively linked to the 3' end of the nucleotide sequence encoding the polypeptide. Any terminator that is functional in a selected host cell can be used in this invention.
[0092] The regulatory sequence can also be a suitable leader sequence, or an untranslated region of mRNA important for translation in the host cell. The leader sequence is operatively linked to the 5′ end of the nucleotide sequence encoding the polypeptide. Any terminator that is functional in a selected host cell can be used in this invention.
[0093] Preferably, the nucleic acid construct is a vector.
[0094] Expression of the CAR-encoding polynucleotide sequence is typically achieved by operatively linking the polynucleotide sequence to a promoter and incorporating the construct into an expression vector. This vector is suitable for replication and integration into eukaryotic cells. A typical cloning vector contains transcription and translation terminators, a start sequence, and a promoter that can be used to regulate the expression of the desired nucleic acid sequence.
[0095] The polynucleotide sequence encoding the CAR of this invention can be cloned into many types of vectors. For example, it can be cloned into plasmids, phage particles, phage derivatives, animal viruses, and granules. Further, the vector is an expression vector. The expression vector can be provided to cells in the form of a viral vector. Viral vector technology is well known in the art. Viruses that can be used as vectors include, but are not limited to, retroviruses, adenoviruses, adeno-associated viruses, herpesviruses, and lentiviruses. Typically, a suitable vector contains at least one origin of replication functioning in an organism, a promoter sequence, a convenient restriction enzyme site, and one or more optional markers.
[0096] More preferably, the nucleic acid construct is a lentiviral vector containing a replication initiation site, a 3'LTR, a 5'LTR, and the aforementioned polynucleotide sequence.
[0097] An example of a suitable promoter is the immediate early cytomegalovirus (CMV) promoter sequence. This promoter sequence is a strongly constitutive promoter sequence capable of driving high-level expression of any polynucleotide sequence operatively linked to it. Another example of a suitable promoter is elongation growth factor-1α (EF-1α). However, other constitutive promoter sequences may also be used, including but not limited to the early promoter of simian virus 40 (SV40), mouse mammary cancer virus (MMTV), human immunodeficiency virus (HIV) long terminal repeat (LTR) promoter, MoMuLV promoter, avian leukemia virus promoter, Epstein-Barr virus immediate early promoter, Russ's sarcoma virus promoter, and human gene promoters such as, but not limited to, actin promoter, myosin promoter, heme promoter, and creatine kinase promoter. Furthermore, the use of inducible promoters may also be considered. The use of inducible promoters provides a molecular switch that enables expression of the polynucleotide sequence operatively linked to the inducible promoter during time-limited expression and disables expression when expression is undesirable. Examples of inducible promoters include, but are not limited to, metallothionein promoters, glucocorticoid promoters, progesterone promoters, and tetracycline promoters.
[0098] To assess the expression of CAR peptides or portions thereof, the expression vector introduced into cells may also contain one or both of optional marker genes or reporter genes to facilitate the identification and selection of expressing cells from a population of cells seeking transfection or infection via a viral vector. Alternatively, the optional marker may be carried on a separate DNA segment and used in co-transfection procedures. Both the optional marker and the reporter gene may have appropriate regulatory sequences flanking them to enable expression in host cells. Useful optional markers include, for example, antibiotic resistance genes such as neo.
[0099] Reporter genes are used to identify potentially transfected cells and to evaluate the functionality of regulatory sequences. After DNA has been introduced into recipient cells, reporter gene expression is measured at an appropriate time. Suitable reporter genes may include genes encoding luciferase, β-galactosidase, chloramphenicol acetyltransferase, secretory alkaline phosphatase, or green fluorescent protein. Suitable expression systems are well-known and can be prepared using known techniques or are commercially available.
[0100] Methods for introducing genes into cells and expressing genes into cells are known in the art. Vectors can be readily introduced into host cells, such as mammalian, bacterial, yeast, or insect cells, by any method in the art. For example, expression vectors can be transferred into host cells by physical, chemical, or biological means.
[0101] Physical methods for introducing polynucleotides into host cells include calcium phosphate precipitation, lipid transfection, particle bombardment, microinjection, electroporation, and others. Biological methods for introducing polynucleotides of interest into host cells include the use of DNA and RNA vectors. Chemical methods for introducing polynucleotides into host cells include colloidal dispersion systems, such as macromolecular complexes, nanocapsules, microspheres, and beads; and lipid-based systems, including oil-in-water emulsions, micelles, mixed micelles, and liposomes.
[0102] Biological methods for introducing polynucleotides into host cells include the use of viral vectors, particularly lentiviral vectors, which have become the most widely used method for inserting genes into mammalian cells, such as human cells. Other viral vectors may be derived from lentiviruses, poxviruses, herpes simplex virus I, adenoviruses, and adeno-associated viruses, among others. Many virus-based systems have been developed for transferring genes into mammalian cells. For example, lentiviruses provide a convenient platform for gene delivery systems. Selected genes can be inserted into vectors and packaged into lentiviral particles using techniques known in the art. The recombinant virus can then be isolated and delivered to target cells in vivo or in vitro. Many retroviral systems are known in the art. In some embodiments, adenoviral vectors are used. Many adenoviral vectors are known in the art. In one embodiment, a lentiviral vector is used.
[0103] The lentivirus provided by this invention contains the aforementioned nucleic acid construct. Preferably, it contains the vector. More preferably, it contains the lentiviral vector.
[0104] The present invention provides a method for activating T cells in vitro, the method comprising the step of infecting the T cells with the aforementioned lentivirus.
[0105] The CAR-T cells of this invention can undergo robust in vivo T cell expansion and persist at high levels for an extended period in the blood and bone marrow, forming specific memory T cells. Without wishing to be bound by any specific theory, the CAR-T cells of this invention can differentiate into a central memory-like state in vivo after encountering and subsequently eliminating target cells expressing alternative antigens.
[0106] This invention also includes a class of cell therapies in which T cells are genetically modified to express the CAR described herein, and CAR-T cells are injected into recipients who require them. The injected cells are able to kill the recipient's tumor cells. Unlike antibody therapies, CAR-T cells can replicate in vivo, producing long-lasting efficacy that can lead to sustained tumor control.
[0107] Antitumor immune responses induced by CAR-T cells can be active or passive. Furthermore, CAR-mediated immune responses can be part of adoptive immunotherapy procedures, in which CAR-T cells induce a specific immune response against the antigen-binding portion of the CAR.
[0108] The treatable cancer can be a non-solid tumor, such as a hematologic malignancy, for example, leukemia and lymphoma. In particular, diseases for which the CAR, its coding sequence, nucleic acid construct, expression vector, virus, and CAR-T cell therapy of the present invention are preferably CD7-mediated diseases, especially CD7-mediated hematologic malignancies.
[0109] Specifically, in this article, "CD7-mediated diseases" include, but are not limited to, leukemia and lymphoma, such as T-cell lymphoma, acute lymphoblastic leukemia, chronic lymphocytic leukemia, hairy cell leukemia, and acute myeloid leukemia.
[0110] The present invention provides a gene-modified T cell or a pharmaceutical composition containing the gene-modified T cell, wherein the cell contains the aforementioned polynucleotide sequence, or contains the aforementioned nucleic acid construct, or is infected with the aforementioned lentivirus, or is prepared by the aforementioned method.
[0111] The CAR-modified T cells of the present invention can be administered alone or as a pharmaceutical composition in combination with a diluent and / or other components such as associated cytokines or cell populations. In short, the pharmaceutical compositions of the present invention may comprise CAR-T cells as described herein, combined with one or more pharmaceutically or physiologically acceptable carriers, diluents, or excipients. Such compositions may include buffers such as neutral buffered saline, sulfate buffered saline, etc.; carbohydrates such as glucose, mannose, sucrose, or dextran, mannitol; proteins; peptides or amino acids such as glycine; antioxidants; chelating agents such as EDTA or glutathione; adjuvants (e.g., aluminum hydroxide); and preservatives.
[0112] The pharmaceutical compositions of the present invention can be administered in a manner suitable for the treatment (or prevention) of a disease. The amount and frequency of administration will be determined by factors such as the patient's condition, and the type and severity of the patient's disease.
[0113] When referring to "immunologically effective amount," "antitumor effective amount," "tumor-suppressive effective amount," or "therapeutic amount," the precise amount of the composition of the invention to be administered can be determined by a physician, taking into account individual differences in the patient's (subject's) age, weight, tumor size, degree of infection or metastasis, and disease condition. It can generally be indicated that a pharmaceutical composition including T cells described herein can be administered in doses of 10... 4 Up to 10 9 A dose of cells / kg body weight, preferably 10. 5 Up to 10 6 The dosage is 1 cell / kg body weight. The T-cell composition can also be administered at these dosages multiple times. Cells can be administered using infusion techniques known in immunotherapy. The optimal dosage and treatment regimen for a specific patient can be readily determined by medical professionals by monitoring the patient's disease signs and thus adjusting the treatment accordingly.
[0114] The application of the target composition can be performed in any convenient manner, including by spraying, injection, swallowing, infusion, implantation, or transplantation. The compositions described herein can be administered to patients subcutaneously, intradermally, intratumorally, intranodally, intraspinally, intramuscularly, intravenously, or intraperitoneally. In one embodiment, the T-cell composition of the present invention is administered to a patient by intradermal or subcutaneous injection. In another embodiment, the T-cell composition of the present invention is preferably administered by intravenous injection. The T-cell composition can be injected directly into the tumor, lymph node, or site of infection.
[0115] In some embodiments of the invention, the CAR-T cells or compositions thereof of the present invention may be combined with other therapies known in the art. These therapies include, but are not limited to, chemotherapy, radiotherapy, and immunosuppressants. For example, treatment may be administered in combination with various radiotherapy agents, including cyclosporine, azathioprine, methotrexate, mycophenolate mofetil, FK506, fludarabine, rapamycin, and mycophenolic acid. In further embodiments, the cell compositions of the present invention are administered to patients in combination with bone marrow transplantation, T-cell ablation therapy using chemotherapeutic agents such as fludarabine, external beam radiotherapy (XRT), cyclophosphamide, or antibodies such as OKT3 or CAMPATH (e.g., before, simultaneously with, or after).
[0116] In this article, "anti-tumor effect" refers to a biological effect that can be represented by a reduction in tumor volume, a reduction in the number of tumor cells, a reduction in the number of metastases, an increase in life expectancy, or an improvement in various cancer-related physiological symptoms.
[0117] The terms "patient," "subject," and "individual" are used interchangeably in this article to refer to a living organism, such as a mammal, that can elicit an immune response. Examples include, but are not limited to, humans, dogs, cats, mice, rats, and their transgenic species.
[0118] The use of the aforementioned chimeric antigen receptor, the aforementioned polynucleotide sequence, the aforementioned nucleic acid construct or the aforementioned lentivirus in the preparation of T cell activators and / or the preparation of T cell degradation inhibitors.
[0119] The aforementioned chimeric antigen receptor, the aforementioned polynucleotide sequence, the aforementioned nucleic acid construct, the aforementioned lentivirus, or the aforementioned genetically modified T cell may be used in any one or more of the following purposes: (1) preparation of tumor therapeutic drugs; (2) preparation of preparations that enhance the killing efficiency against tumors; (3) preparation of preparations that maintain the proliferative capacity of T cells; (4) preparation of preparations that inhibit tumor development.
[0120] Preferably, the tumor is selected from one or more of leukemia or lymphoma.
[0121] More preferably, the tumor is selected from T-cell lymphoma, acute lymphoblastic leukemia, chronic lymphoblastic leukemia, hairy cell leukemia, and acute myeloid leukemia.
[0122] Example 1: Construction of CAR vectors
[0123] The antigen-specific antibody sequence targeting the human CD7 protein CAR used in this invention was obtained by the following method: The extracellular terminal sequence of recombinant human CD7 protein was used as the antigen, immobilized in a high-absorption plate, and then a nanobody phage display library was added (the nanobody phage display library was constructed in our laboratory; the library design references are Zhong Z, Yang Y, Chen X, Han Z, Zhou J, Li B, He X. Positive charge in the complementarity-determining regions of synthetic nanobody prevents aggregation. Biochem Biophys Res Commun. 2021 Oct1;572:1-6. doi:10.1016 / j.bbrc.2021.07.054.Epub 2021 Jul 28.PMID:34332323. and McMahon C, Baier AS, Pascolutti R, Wegrecki M, Zheng S, Ong JX, Erlandson SC, Hilger D, Rasmussen SGF, Ring AM, Manglik A, Kruse AC. Yeast surface display platform for rapid discovery of conformationally selective nanobodies. Nat Struct MolBiol. 2018 Mar;25(3):289-296. doi:10.1038 / s41594-018-0028-6. Epub 2018 Feb12. PMID:29434346;PMCID:PMC5839991. References for the construction of phage display libraries: Tonikian R, Zhang Y, Boone C, Sidhu SS. Identifying specificity profiles for peptide recognition modules from phage-displayed peptide libraries. Nat Protoc.2007;2(6):1368-86.doi:10.1038 / nprot.2007.151.PMID:17545975.) After binding with the antigen and removing unbound phages, the phages bound to the antigen are recovered and amplified. The phages in the amplified products are then used for a second round of screening, and this process is repeated.Four rounds of screening were conducted, from which 156 positive clones were selected. After sequencing, repetitive sequences were removed to obtain 14 different nanobody sequences, which were then constructed into CARs.
[0124] The extracellular segment of the CAR is composed of a CD8α signal peptide sequence, a myc tag sequence, a nanobody sequence, and a CD8α hinge sequence tandemly; the transmembrane region sequence is the transmembrane region sequence of CD8α; the intracellular segment structure is composed of a human 41BB molecule intracellular segment sequence tandemly with a human CD3ζ intracellular segment sequence. In this invention, all CAR base sequences were ultimately cloned into the pHR-hEF1α-IRES-EGFP vector via Gibson ligation.
[0125] Example 2: Human primary T cell culture, CD7 protein knockout and lentiviral infection
[0126] Primary T cells were obtained from healthy informed volunteers. Primary T cells were cultured in RPMI-1640 medium containing 10% fetal bovine serum, 100 U / ml penicillin, 100 μg / ml streptomycin sulfate, 1 mM sodium pyruvate, non-essential amino acids, and 55 μM 2-mercaptoethanol (all reagents were purchased from Gibco). To maintain T cell proliferation, 200 U / ml hIL-2 (Sigma-Aldrich) was added to the medium.
[0127] Preparation of lentivirus: 6.5 × 10 5 Lenti-X 293T cells (TaKaRa#632180) were resuspended in DMEM medium (Gibco#11995-065) containing 10% fetal bovine serum and seeded in 6-well cell culture plates (Corning#CLS3516) for 24 hours. Using a liposome transfection system (Mirus#2300), 650 ng of the retroviral packaging plasmid Gel-pol and 400 ng of VSVG were mixed with 2 μg of the lentiviral plasmid to be packaged, following the liposome transfection instructions, and then added to the Lenti-X 293T cells. After 16-18 hours, the liposome-containing medium was discarded, and an appropriate amount of fresh medium was added. After 48 hours, the cell supernatant was collected, concentrated directly or by ultracentrifugation, and then frozen at -80°C for later use.
[0128] Electroporation to knock out CD7 protein using RNP: CD7 protein knockout gRNA was ordered from Nanjing GenScript Co., Ltd., with the sequence: ggagcaggtgatgttgacgg (SEQ ID NO: 24), diluted to 50 μM with RNase-free water. Cas9 protein was ordered from Beijing Sinocare Technology Co., Ltd. (cat#40572-A08B), diluted to 30 μM with RNase-free water. Unactivated human primary T cells were electroporated using the Lonza-Amaxa™ P2 Primary Cell 4D-Nucleofector™ X Kit S according to the manufacturer's instructions to knock out CD7 protein.
[0129] Lentiviral infection of primary T cells: Untreated TC-treated 96-well cell culture plates (100 μL / well) were coated with anti-human CD3 antibody (4 μg / ml) and anti-human CD28 antibody (4 μg / ml) to activate T cells that had recovered for 24 hours after electroporation. After 24 hours of culture, prepared retrovirus and polybrene at a final concentration of 4-8 μg / ml were added, followed by centrifugation (2000 rpm, 37°C, 1 hour, ramp 2, depress 0). After 24 hours, the culture medium containing the virus was discarded and replaced with fresh T cell complete culture medium. After 4-5 days of T cell stimulation, the cells were transferred to uncoated culture plates for further culture. The cell density was adjusted to 0.8-1 × 10^6 / ml with T cell complete culture medium, and fresh T cell complete culture medium was added every 2 days to maintain the cell density.
[0130] Example 3: Flow Cytometry Analysis
[0131] For staining of cell surface markers: Dilute the antibody in FACS buffer (phosphate-buffered saline PBS + 2% fetal bovine serum) at an appropriate ratio, resuspend the cells in an appropriate amount of antibody dilution, and incubate them together at 4°C in the dark for 25 minutes; wash the cells three times with FACS buffer, resuspend the cells in FACS buffer containing an appropriate concentration of DAPI, and then perform the detection.
[0132] Flow cytometry data were acquired using a BD LSRFortessa machine (BD Bioscience) and analyzed using FlowJo software (Tree Star). A list of antibodies used in the flow cytometry is provided below.
[0133]
[0134]
[0135] Example 4: CAR-T in vitro killing function test
[0136] Both CD7-positive and CD7-negative target cells expressed the firefly luciferase gene. After counting target cells and CAR-T cells, the required amount of cells was collected, centrifuged, and the original culture medium was discarded. The cells were then resuspended in IL-2-free T cell complete culture medium to the appropriate volume. Based on the effector-target (E:T) ratio, different amounts of CAR-T cells and the same amount of target cells were added to black 96-well cell culture plates. Sample wells containing only an equal amount of target cells were also prepared. After mixing, the plates were incubated statically for 16 hours. For detection, the firefly luciferase substrate fluorescein was added to a final concentration of 1.5 mg / ml, and the fluorescence value in each well was quickly read using a microplate reader. The fluorescence reading of the sample well containing only an equal amount of target cells was used as the baseline value (F0) to calculate the ratio of target cells to non-target cells killed in each sample. The calculation formula is as follows:
[0137] Killing efficiency (%) = (Fluorescence reference value F0 - Sample fluorescence value Fx) / F0 * 100%
[0138] Example 5: ELISA detection of cytokine secretion levels in CAR-T cells
[0139] After counting target cells and CAR-T cells, the required amount of cells were collected, centrifuged, and the original culture medium was discarded. The cells were then resuspended in IL-2-free T cell complete culture medium to the appropriate volume. A certain amount of CAR-T cells and different amounts of target cells were co-incubated according to the indicated E:T ratio. After mixing, the cells were incubated statically in a cell culture incubator for 16 hours. The culture supernatant was collected, and the levels of cytokines such as IL-2 and IFN-γ were detected according to the ELISA kit instructions.
[0140] Example 6: Detection of CAR-T cell proliferation capacity in vitro
[0141] E7-BBζ WT and E7-BBζ KR After CAR-T cell counting, the cells were mixed 1:1 with irradiated target cells, CD7-positive Jurkat cells, and resuspended in IL-2-free T cell complete culture medium until the cell density reached 1*10^6 / ml. Viable cell counts were performed every 2 days to calculate cell proliferation, and the cell density was adjusted to 1*10^6 / ml in IL-2-free T cell complete culture medium. When the cell density obtained from the viable cell count was less than or equal to 1*10^6 / ml, it indicated that the cells had stopped proliferating and the experiment was terminated.
[0142] Example 7: Mouse tumor model and CAR-T cell function detection
[0143] The in vivo experimental subjects were 5- to 8-week-old combined immunodeficient (NSG) mice. To compare the in vivo antitumor effect of CAR-T, NSG mice were first injected via the tail vein with 1×10⁻⁶ CAR-T cells. 6 CD7-positive Jurkat cells expressing the firefly luciferase gene were administered to NSG mice via tail vein injection after the target cells had grown in vivo for 4 days. 6 CAR-T cell therapy was administered weekly; the intensity of firefly luciferase carried by mouse tumor cells was detected weekly using a small animal in vivo imaging system to track tumor development in vivo. The specific procedures for using the small animal in vivo imaging system included: intraperitoneal injection of firefly luciferase substrate (D-luciferin sodium salt) into tumor-bearing mice at a dosage of 0.15 mg / g mouse body weight; after 10 minutes, once the substrate had fully circulated throughout the mouse, the mice were anesthetized with 2.5%-3.5% isoflurane gas before imaging. Bioluminescence imaging was performed using an IVIS spectral imaging system (Perkin Elmer), and quantitative fluorescence data were obtained using in vivo imaging software (Perkin Elmer). Mouse death time was recorded, or mice were euthanized when their tumor burden reached the experimental endpoint, and the time of death was recorded, along with the mouse survival rate.
[0144] Example 8: Analysis of Experimental Results
[0145] Using in vitro purified recombinant human CD7 protein (sino-biological, cat#11028-H08H) as the antigen, the nanobody phages in Example 1 were screened. After four rounds of screening, single phage clones were selected for ELISA detection. Clones that could recognize the antigen human CD7 protein but not the control protein bovine serum albumin (BSA) were selected. These clones were then sequenced and their sequences were aligned to remove repetitive sequences. The ELISA results of some positive single clones are shown below. Figure 1 As shown.
[0146] Nanobodies that specifically recognize the CD7 protein, selected by ELISA, were constructed as CARs. This is compared with a previously reported CD7-targeting CAR (PA7-13). (Chen D, You F, Xiang S, et al. Chimeric antigen receptor T cells derived from CD7 nanobody. exhibit robust antitumor potential against CD7-positive malignancies. Am J Cancer Res. 2021; 11(11):5263-5281. Published 2021 Nov) 15)MALPVTALLLPLALLLHAARPEQKLISEEDLMQVQLVESGGGLVQPGGSLRLSCAASGYPYSSYCMGWFRQAPGQGLEAVAAIDSDGRTRYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAARFGPMGCVDLSTLSFGHWGQGTLVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGA VHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYQQGQNQL YNELNLGRREEYDVLDKRRGRDPEMGGKPQRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR(SEQ ID NO: 25) was expressed on the CD7 knockout human T cell line jurakat. After staining with the surface antigen, the expression of CAR on the cell membrane and the self-activation level of CAR-T cells in the resting state were detected by flow cytometry. The results are as follows: Figure 2 As shown, the nanobodies D2, D4, and E7 CARs have high expression levels on the cell membrane and low background self-activation levels, which better meet our screening criteria.
[0147] CARs (SEQ ID NO: 12-15) constructed from three nanobodies (D2, D4, and E7) and PA7-13 were expressed on CD7-knockout human primary T cells. After staining with cell surface antigens, flow cytometry was used to detect their expression on the cell membrane, as well as their basal autoactivation level and the level of cell exhaustion caused by this autoactivation signal in the resting state. The results are as follows: Figure 3As shown, excessively strong basal autoactivation signals can lead to premature cell exhaustion of CAR-T cells even before they are stimulated by target cells. Exhausted T cells not only exhibit significantly reduced proliferative capacity, but also a substantial decrease in tumor cell killing ability and cytokine release levels. In the above experiments, the three nanobody CARs screened and constructed showed low basal autoactivation levels and low levels of induced cell exhaustion, suggesting that they may possess strong sustained proliferative capacity and tumor-killing function.
[0148] CARs constructed from three nanobodies (D2, D4, and E7) and PA7-13 were expressed in the CD7-knockout human T cell line jurakat. After co-incubation for 16 hours with CD7-positive target cells and CD7-negative non-target cells at different effector-target cell ratios (E:T), the activation levels were detected by flow cytometry after staining with surface antigens. Results are as follows: Figure 4 As shown, the three different nanobody CARs constructed in this invention can effectively recognize CD7 protein on target cells, thereby activating T cells and significantly upregulating the expression of the T cell activation indicator protein CD69, while showing almost no response to stimulation of CD7 protein-negative target cells.
[0149] CARs constructed from three nanobodies (D2, D4, and E7) and PA7-13 were expressed on CD7-knockout human primary T cells. After co-incubating these cells with CD7-positive target cells at different E:T ratios for 16 hours, the fluorescence intensity produced by the firefly luciferase expressed on the target cells, which consumed its substrate luciferin, reflected the killing ability of the cells. Figure 5 It is evident that the three types of CAR-T cells constructed in this invention can effectively recognize and kill tumor target cells. Among them, the CAR constructed from nanobody E7 has the lowest background self-activation level and the most significant response to human CD7 antigen. Therefore, this invention will take the CAR constructed from E7 as an example to further verify its function.
[0150] After expressing the E7 nanobody CAR on human primary T cells with CD7 protein knockout, its cytotoxic function against target and non-target cells was tested. CAR-T cells and control T cells were co-incubated with CD7-positive target cells and CD7-negative non-target cells at different effector-target cell ratios (E:T) for 16 hours. Then, luciferin, the substrate of the firefly luciferase expressed by the target cells, was administered. The intensity of the characteristic fluorescent signal produced by luciferin under the action of firefly luciferase was detected using a microplate reader, thus reflecting the number of surviving target and non-target cells. Figure 7As shown, E7CAR can specifically recognize CD7-positive target cells and mediate CAR-T cells to kill tumor cells specifically and efficiently.
[0151] CAR-T cells and control T cells were co-incubated with CD7-positive target cells at different effector-target cell ratios (E:T) for 16 hours. The culture supernatant was then collected, and the secretion levels of effector cytokines IL-2 and IFN-γ in the supernatant were detected by ELISA. Results are as follows: Figure 8 As shown, E7 CAR-T cells can effectively respond to the stimulation of CD7-positive tumor target cells, secreting large amounts of effector cytokines related to T cell proliferation and function, thereby further stimulating a stronger immune response and playing a synergistic role in killing tumors.
[0152] This invention uses a 1:1 effector cell:target cell ratio to administer wild-type E7 CAR-T cells and ubiquitination-deficient E7 CAR-T cells (i.e., CAR-modified T cells of SEQ ID NO: 15 and CAR-modified T cells of SEQ ID NO: 16) with a certain amount of irradiated target cells for stimulation. Viable cell counts are performed every 2 days, cell proliferation is recorded, and appropriate amounts of culture medium are added to adjust the cell density to 1*10^6 / ml. Target cell stimulation is repeated every 6 days. The experimental results are as follows: Figure 8 The results showed that CAR-T cells lacking ubiquitination modification, especially in the presence of target cells and under continuous stimulation, had a stronger and more significant sustained proliferative capacity, suggesting that they may have a stronger, more effective and sustained tumor-killing ability.
[0153] Tumor-bearing mice were randomly divided into two groups, and were administered equal amounts of untransfected normal T cells and E7 CAR cells via tail vein injection, respectively. KR (Ubiquitin-deficient) T cells were used to track tumor cell growth in mice using an in vivo imaging system (IVIS). Results were as follows: Figure 9 As shown, when an equal number of T cells were infused, T cells without CAR transfection had almost no effective killing function against tumors, while E7 CAR-T cells lacking ubiquitination modification were able to effectively control the growth of tumor target cells and significantly improve the survival rate of mice.
[0154] The above description is merely a preferred embodiment of the present invention and is not intended to limit the present invention in any form or substance. It should be noted that those skilled in the art can make various improvements and additions without departing from the method of the present invention, and these improvements and additions should also be considered within the scope of protection of the present invention. Any modifications, alterations, and equivalent changes made by those skilled in the art based on the above-disclosed technical content without departing from the spirit and scope of the present invention are equivalent embodiments of the present invention. Furthermore, any modifications, alterations, and evolutions made to the above embodiments based on the essential technology of the present invention still fall within the scope of the technical solution of the present invention. sequence list <110> Shanghai First People's Hospital <120> A chimeric antigen receptor targeting CD7 protein and its applications <160> 25 <170> SIPOSequenceListing 1.0 <210> 1 <211> 127 <212> PRT <213> Artificial Sequence <400> 1 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Pro Tyr 20 25 30 Val Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Gly Arg Glu Leu Val 35 40 45 Ala Asp Ile Ser Ser Ser Gly Gly Ser Thr Tyr Tyr Pro Asp Ser Val 50 55 60 Glu Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Arg Met Val Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Ala Lys Pro Trp Pro Pro Phe Gly Pro Tyr Thr Tyr Ala Tyr Asn 100 105 110 Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser Gly Gly Ser 115 120 125 <210> 2 <211> 127 <212> PRT <213> Artificial Sequence <400> 2 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ile Thr Phe Ser Thr Tyr 20 25 30 Asn Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Gly Arg Glu Leu Val 35 40 45 Ala Ala Ile Ser Arg Thr Gly Gly Ser Thr Tyr Tyr Pro Asp Ser Val 50 55 60 Glu Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Arg Met Val Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Ala Ser Leu Tyr Pro Asp Gly Tyr Leu Ser Ile Tyr Ser Tyr Asn 100 105 110 Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser Gly Gly Ser 115 120 125 <210> 3 <211> 131 <212> PRT <213> Artificial Sequence <400> 3 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Thr Asn 20 25 30 Arg Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Gly Arg Glu Leu Val 35 40 45 Ala Ala Ile Asn Ser Arg Asp Ser Arg Thr Trp Tyr Pro Asp Ser Val 50 55 60 Glu Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Arg Met Val Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Ala Gly Gly Glu Ile Tyr Ser Leu Gly Asp Asp Trp Phe Gly Trp 100 105 110 Gly Pro Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115 120 125 Gly Gly Ser 130 <210> 4 <211> 42 <212> PRT <213> Artificial Sequence <400> 4 Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met 1 5 10 15 Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe 20 25 30 Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu 35 40 <210> 5 <211> 113 <212> PRT <213> Artificial Sequence <400> 5 Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly 1 5 10 15 Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr 20 25 30 Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys 35 40 45 Pro Gln Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln 50 55 60 Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu 65 70 75 80 Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr 85 90 95 Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro 100 105 110 Arg <210> 6 <211> 155 <212> PRT <213> Artificial Sequence <400> 6 Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met 1 5 10 15 Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe 20 25 30 Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu Arg Val Lys Phe Ser Arg 35 40 45 Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn 50 55 60 Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg 65 70 75 80 Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Gln Arg Arg Lys Asn 85 90 95 Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu 100 105 110 Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly 115 120 125 His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr 130 135 140 Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg 145 150 155 <210> 7 <211> 155 <212> PRT <213> Artificial Sequence <400> 7 Arg Arg Gly Arg Arg Arg Leu Leu Tyr Ile Phe Arg Gln Pro Phe Met 1 5 10 15 Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe 20 25 30 Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu Arg Val Arg Phe Ser Arg 35 40 45 Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn 50 55 60 Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Arg Arg 65 70 75 80 Arg Gly Arg Asp Pro Glu Met Gly Gly Arg Pro Gln Arg Arg Arg Asn 85 90 95 Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Arg Asp Arg Met Ala Glu 100 105 110 Ala Tyr Ser Glu Ile Gly Met Arg Gly Glu Arg Arg Arg Gly Arg Gly 115 120 125 His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Arg Asp Thr Tyr 130 135 140 Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg 145 150 155 <210> 8 <211> 10 <212> PRT <213> Artificial Sequence <400> 8 Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu 1 5 10 <210> 9 <211> 21 <212> PRT <213> Artificial Sequence <400> 9 Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu 1 5 10 15 His Ala Ala Arg Pro 20 <210> 10 <211> 45 <212> PRT <213> Artificial Sequence <400> 10 Thr Thr Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala 1 5 10 15 Ser Gln Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly 20 25 30 Gly Ala Val His Thr Arg Gly Leu Asp Phe Ala Cys Asp 35 40 45 <210> 11 <211> 21 <212> PRT <213> Artificial Sequence <400> 11 Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly Val Leu Leu Leu 1 5 10 15 Ser Leo Val Ile Thr 20 <210> 12 <211> 382 <212> PRT <213> Artificial Sequence <400> 12 Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu 1 5 10 15 His Ala Ala Arg Pro Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu Glu 20 25 30 Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser 35 40 45 Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Pro Tyr Val 50 55 60 Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Gly Arg Glu Leu Val Ala 65 70 75 80 Asp Ile Ser Ser Ser Gly Gly Ser Thr Tyr Tyr Pro Asp Ser Val Glu 85 90 95 Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Arg Met Val Tyr Leu 100 105 110 Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala 115 120 125 Ala Lys Pro Trp Pro Pro Phe Gly Pro Tyr Thr Tyr Ala Tyr Asn Tyr 130 135 140 Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser Gly Gly Ser Thr Thr 145 150 155 160 Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln 165 170 175 Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala 180 185 190 Val His Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala 195 200 205 Pro Leu Ala Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr 210 215 220 Leu Tyr Cys Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln 225 230 235 240 Pro Phe Met Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser 245 250 255 Cys Arg Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu Arg Val Lys 260 265 270 Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln 275 280 285 Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu 290 295 300 Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Gln Arg 305 310 315 320 Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys 325 330 335 Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg 340 345 350 Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys 355 360 365 Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg 370 375 380 <210> 13 <211> 382 <212> PRT <213> Artificial Sequence <400> 13 Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu 1 5 10 15 His Ala Ala Arg Pro Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu Glu 20 25 30 Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser 35 40 45 Leu Arg Leu Ser Cys Ala Ala Ser Gly Ile Thr Phe Ser Thr Tyr Asn 50 55 60 Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Gly Arg Glu Leu Val Ala 65 70 75 80 Ala Ile Ser Arg Thr Gly Gly Ser Thr Tyr Tyr Pro Asp Ser Val Glu 85 90 95 Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Arg Met Val Tyr Leu 100 105 110 Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala 115 120 125 Ala Ser Leu Tyr Pro Asp Gly Tyr Leu Ser Ile Tyr Ser Tyr Asn Tyr 130 135 140 Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser Gly Gly Ser Thr Thr 145 150 155 160 Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln 165 170 175 Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala 180 185 190 Val His Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala 195 200 205 Pro Leu Ala Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr 210 215 220 Leu Tyr Cys Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln 225 230 235 240 Pro Phe Met Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser 245 250 255 Cys Arg Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu Arg Val Lys 260 265 270 Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln 275 280 285 Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu 290 295 300 Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Gln Arg 305 310 315 320 Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys 325 330 335 Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg 340 345 350 Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys 355 360 365 Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg 370 375 380 <210> 14 <211> 386 <212> PRT <213> Artificial Sequence <400> 14 Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu 1 5 10 15 His Ala Ala Arg Pro Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu Glu 20 25 30 Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser 35 40 45 Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Thr Asn Arg 50 55 60 Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Gly Arg Glu Leu Val Ala 65 70 75 80 Ala Ile Asn Ser Arg Asp Ser Arg Thr Trp Tyr Pro Asp Ser Val Glu 85 90 95 Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Arg Met Val Tyr Leu 100 105 110 Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala 115 120 125 Ala Gly Gly Glu Ile Tyr Ser Leu Gly Asp Asp Trp Phe Gly Trp Gly 130 135 140 Pro Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser Gly 145 150 155 160 Gly Ser Thr Thr Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr 165 170 175 Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala 180 185 190 Ala Gly Gly Ala Val His Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile 195 200 205 Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly Val Leu Leu Leu Ser 210 215 220 Leu Val Ile Thr Leu Tyr Cys Lys Arg Gly Arg Lys Lys Leu Leu Tyr 225 230 235 240 Ile Phe Lys Gln Pro Phe Met Arg Pro Val Gln Thr Thr Gln Glu Glu 245 250 255 Asp Gly Cys Ser Cys Arg Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu 260 265 270 Leu Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln 275 280 285 Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu 290 295 300 Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly 305 310 315 320 Lys Pro Gln Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu 325 330 335 Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly 340 345 350 Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser 355 360 365 Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro 370 375 380 Pro Arg 385 <210> 15 <211> 386 <212> PRT <213> Artificial Sequence <400> 15 Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu 1 5 10 15 His Ala Ala Arg Pro Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu Glu 20 25 30 Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser 35 40 45 Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Thr Asn Arg 50 55 60 Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Gly Arg Glu Leu Val Ala 65 70 75 80 Ala Ile Asn Ser Arg Asp Ser Arg Thr Trp Tyr Pro Asp Ser Val Glu 85 90 95 Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Arg Met Val Tyr Leu 100 105 110 Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala 115 120 125 Ala Gly Gly Glu Ile Tyr Ser Leu Gly Asp Asp Trp Phe Gly Trp Gly 130 135 140 Pro Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser Gly 145 150 155 160 Gly Ser Thr Thr Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr 165 170 175 Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala 180 185 190 Ala Gly Gly Ala Val His Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile 195 200 205 Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly Val Leu Leu Leu Ser 210 215 220 Leu Val Ile Thr Leu Tyr Cys Arg Arg Gly Arg Arg Arg Leu Leu Tyr 225 230 235 240 Ile Phe Arg Gln Pro Phe Met Arg Pro Val Gln Thr Thr Gln Glu Glu 245 250 255 Asp Gly Cys Ser Cys Arg Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu 260 265 270 Leu Arg Val Arg Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln 275 280 285 Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu 290 295 300 Tyr Asp Val Leu Asp Arg Arg Arg Gly Arg Asp Pro Glu Met Gly Gly 305 310 315 320 Arg Pro Gln Arg Arg Arg Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu 325 330 335 Gln Arg Asp Arg Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Arg Gly 340 345 350 Glu Arg Arg Arg Gly Arg Gly His Asp Gly Leu Tyr Gln Gly Leu Ser 355 360 365 Thr Ala Thr Arg Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro 370 375 380 Pro Arg 385 <210> 16 <211> 382 <212> PRT <213> Artificial Sequence <400> 16 Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu 1 5 10 15 His Ala Ala Arg Pro Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu Glu 20 25 30 Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser 35 40 45 Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Pro Tyr Val 50 55 60 Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Gly Arg Glu Leu Val Ala 65 70 75 80 Asp Ile Ser Ser Ser Gly Gly Ser Thr Tyr Tyr Pro Asp Ser Val Glu 85 90 95 Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Arg Met Val Tyr Leu 100 105 110 Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala 115 120 125 Ala Lys Pro Trp Pro Pro Phe Gly Pro Tyr Thr Tyr Ala Tyr Asn Tyr 130 135 140 Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser Gly Gly Ser Thr Thr 145 150 155 160 Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln 165 170 175 Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala 180 185 190 Val His Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala 195 200 205 Pro Leu Ala Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr 210 215 220 Leu Tyr Cys Arg Arg Gly Arg Arg Arg Leu Leu Tyr Ile Phe Arg Gln 225 230 235 240 Pro Phe Met Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser 245 250 255 Cys Arg Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu Arg Val Arg 260 265 270 Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln 275 280 285 Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu 290 295 300 Asp Arg Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Arg Pro Gln Arg 305 310 315 320 Arg Arg Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Arg Asp Arg 325 330 335 Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Arg Gly Glu Arg Arg Arg 340 345 350 Gly Arg Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Arg 355 360 365 Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg 370 375 380 <210> 17 <211> 382 <212> PRT <213> Artificial Sequence <400> 17 Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu 1 5 10 15 His Ala Ala Arg Pro Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu Glu 20 25 30 Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser 35 40 45 Leu Arg Leu Ser Cys Ala Ala Ser Gly Ile Thr Phe Ser Thr Tyr Asn 50 55 60 Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Gly Arg Glu Leu Val Ala 65 70 75 80 Ala Ile Ser Arg Thr Gly Gly Ser Thr Tyr Tyr Pro Asp Ser Val Glu 85 90 95 Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Arg Met Val Tyr Leu 100 105 110 Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala 115 120 125 Ala Ser Leu Tyr Pro Asp Gly Tyr Leu Ser Ile Tyr Ser Tyr Asn Tyr 130 135 140 Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser Gly Gly Ser Thr Thr 145 150 155 160 Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln 165 170 175 Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala 180 185 190 Val His Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala 195 200 205 Pro Leu Ala Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr 210 215 220 Leu Tyr Cys Arg Arg Gly Arg Arg Arg Leu Leu Tyr Ile Phe Arg Gln 225 230 235 240 Pro Phe Met Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser 245 250 255 Cys Arg Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu Arg Val Arg 260 265 270 Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln 275 280 285 Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu 290 295 300 Asp Arg Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Arg Pro Gln Arg 305 310 315 320 Arg Arg Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Arg Asp Arg 325 330 335 Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Arg Gly Glu Arg Arg Arg Arg 340 345 350 Gly Arg Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Arg 355 360 365 Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg 370 375 380 <210> 18 <211> 1146 <212> DNA <213> Artificial Sequence <400> 18 atggccttac cagtgaccgc cttgctcctg ccgctggcct tgctgctcca cgccgccagg 60 ccggaacaga agctgatctc ggaggaggat ctggaggtgc agctggtgga gagcggtggt 120 ggtctcgtgc agcccggcgg tagtctgcgc ctcagctgtg ccgccagcgg tcgcaccttt 180 agcccatatg tgatgggctg gtttcgccaa gcccccggca aaggtcgcga actggtggcc 240 gatattagca gcagcggtgg cagcacctac tacccagata gcgtggaagg ccgcttcacc 300 atcagccgcg ataacgccaa gcgcatggtg tatctgcaga tgaacagtct gcgcgccgag 360 gacaccgccg tgtattattg tgccgccaaa ccatggccac catttggccc atatacctat 420 gcctacaatt actggggcca aggcacccaa gtgaccgtga gcagcggtgg ttctaccacc 480 actcccgcac cccgccctcc tactcctgcc cctaccattg ctagccaacc gcttagtctg 540 agacctgagg cctgtaggcc cgctgctggt ggcgctgtgc acacccgagg attggacttc 600 gcttgcgaca tctacatctg ggcacctctg gctgggacct gcggcgtgtt gttgttgagc 660 ctggtgatta cgctgtactg taaacggggc agaagaaac tcctgtatat attcaaaaa 720 ccatttatga gaccagtaca aactactcaa gagaagatg gctgtagctg ccgatttcca 780 gaagaaag aaggaggatg tgaactgaga gtgaagttca gcaggagcgc agacgcccc 840 gcgtaccagc agggccagaa ccagctctat aacgagctca atctaggacg aagagaggag 900 tacgatgttt tggacaagag acgtggccgg gaccctgaga tgggggaaa gccgcagaga 960 aggaagaacc ctcaggaagg cctgtacaat gaactgcaga aagataagat ggcggaggcc 1020 tacagtgaga ttgggatgaa aggcgagcgc cggaggggca aggggcacga tggcctttac 1080 cagggtctca gtacagccac caaggacacc tacgacgccc ttcacatgca ggccctgcct 1140 cctcgc 1146 <210> 19 <211> 1146 <212> DNA <213> Artificial Sequence <400> 19 atggccttac cagtgaccgc cttgctcctg ccgctggcct tgctgctcca cgccgccagg 60 ccggaacaga agctgatctc ggaggaggat ctggaggtgc agctggtgga gagcggtggt 120 ggtctcgtgc agcccggcgg tagtctgcgc ctcagctgtg ccgccagcgg tatcaccttt 180 agcacctata acatgggctg gtttcgccaa gcccccggca aaggtcgcga actggtggcc 240 gccatttccc gcacgggcgg tagcacctac tacccagata gcgtggaagg ccgcttcacc 300 atcagccgcg ataacgccaa gcgcatggtg tatctgcaga tgaacagtct gcgcgccgag 360 gacaccgccg tgtattattg tgccgccagc ctgtatccag atggctatct gagcatctat 420 agctacaatt actggggcca aggcacccaa gtgaccgtga gcagcggtgg ttctaccacc 480 actcccgcac cccgccctcc tactcctgcc cctaccattg ctagccaacc gcttagtctg 540 agacctgagg cctgtaggcc cgctgctggt ggcgctgtgc acacccgagg attggacttc 600 gcttgcgaca tctacatctg ggcacctctg gctgggacct gcggcgtgtt gttgttgagc 660 ctggtgatta cgctgtactg taaacggggc agaaagaaac tcctgtatat attcaaacaa 720 ccatttatga gaccagtaca aactactcaa gaggaagatg gctgtagctg ccgatttcca 780 gaagaagaag aaggaggatg tgaactgaga gtgaagttca gcaggagcgc agacgccccc 840 gcgtaccagc agggccagaa ccagctctat aacgagctca atctaggacg aagagaggag 900 tacgatgttt tggacaagag acgtggccgg gaccctgaga tggggggaaa gccgcagaga 960 aggaagaacc ctcaggaagg cctgtacaat gaactgcaga aagataagat ggcggaggcc 1020 tacagtgaga ttgggatgaa aggcgagcgc cggaggggca aggggcacga tggcctttac 1080 cagggtctca gtacagccac caaggacacc tacgacgccc ttcacatgca ggccctgcct 1140 cctcgc 1146 <210> 20 <211> 1158 <212> DNA <213> Artificial Sequence <400> 20 atggccttac cagtgaccgc cttgctcctg ccgctggcct tgctgctcca cgccgccagg 60 ccggaacaga agctgatctc ggaggaggat ctggaggtgc agctggtgga gagcggtggt 120 ggtctcgtgc agcccggcgg tagtctgcgc ctcagctgtg ccgccagcgg tcgcaccttt 180 agcaccaatc gcatgggctg gtttcgccaa gccccccggca aaggtcgcga actggtggcc 240 gccttaaca gccgcgatag ccgcacctgg tacccagata gcgtggaagg ccgcttcacc 300 atcagccgcg ataacgccaa gcgcatggtg tatctgcaga tgaacagtct gcgcgccgag 360 gacaccgccg tgtattattg tgccgccggc ggcgaaatct atagcctggg cgatgattgg 420 tttgggctgg gcccatacga ttactggggc caaggcacc aagtgaccgt gagcagcggt 480 ggttctacca ccactcccgc accccgccct cctactcctg cccctacat tgctagccaa 540 ccgcttagtc tgagacctga ggcctgtagg cccgctgctg gtggcgctgt gcacacccga 600 ggattggact tcgcttgcga catctacatc tgggcacctc tggctggac ctgcggcgtg 660 ttgttgttga gcctggtgat tacgctgtac tgtaaacggg gcaagaagaa actcctgtat 720 atattcaaac aaccatttat gagaccagta caaactactc aagagaaga tggctgtagc 780 840 gcagacgccc ccgcgtacca gcagggccag aaccagctct ataacgagct caatctagga 900 cgaagagagg agtacgatgt tttggacaag agacgtggcc gggaccctga gatgggggga 960 aagccgcaga gaaggaagaa ccctcaggaa ggcctgtaca atgaactgca gaaagataag 1020 atggcggagg cctacagtga gattgggatg aaaggcgagc gccggagggg caaggggcac 1080 gatggccttt accagggtct cagtacagcc accaaggaca cctacgacgc ccttcacatg 1140 caggccctgc ctcctcgc 1158 <210> 21 <211> 1158 <212> DNA <213> Artificial Sequence <400> 21 atggccttac cagtgaccgc cttgctcctg ccgctggcct tgctgctcca cgccgccagg 60 ccggaacaga agctgatctc ggaggaggat ctggaggtgc agctggtgga gagcggtggt 120 ggtctcgtgc agcccggcgg tagtctgcgc ctcagctgtg ccgccagcgg tcgcaccttt 180 agcaccaatc gcatgggctg gtttcgccaa gcccccggca aaggtcgcga actggtggcc 240 gccattaaca gccgcgatag ccgcacctgg tacccagata gcgtggaagg ccgcttcacc 300 atcagccgcg ataacgccaa gcgcatggtg tatctgcaga tgaacagtct gcgcgccgag 360 gacaccgccg tgtattattg tgccgccggc ggcgaaatct atagcctggg cgatgattgg 420 tttgggctgg gcccatacga ttactggggc caaggcacc aagtgaccgt gagcagcggt 480 ggttctacca ccactcccgc accccgccct cctactcctg cccctacat tgctagccaa 540 ccgcttagtc tgagacctga ggcctgtagg cccgctgctg gtggcgctgt gcacacccga 600 ggattggact tcgcttgcga catctacatc tgggcacctc tggctggac ctgcggcgtg 660 ttgttgttga gcctggtgat tacgctgtac tgtagacggg gcagacgcag actcctgtat 720 atattccgcc aaccatttat gagaccagta caaactactc aagagaaga tggctgtagc 780 840 gcagacgccc ccgcgtacca gcagggccag aaccagctct ataacgagct caatctagga 900 cgaagagagg agtacgatgt tttggaccgc agacgtggcc gggaccctga gatggggga 960 agaccgcaga gaaggcgcaa ccctcaggaa ggcctgtaca atgaactgca gcgcgataga 1020 atggcggagg cctacagtga gattgggatg agaggcgagc gccggagggg cagagggcac 1080 gatggccttt accagggtct cagtacagcc acccgcgaca cctacgacgc ccttcacatg 1140 caggccctgc ctcctcgc 1158 <210> 22 <211> 1146 <212> DNA <213> Artificial Sequence <400> 22 atggccttac cagtgaccgc cttgctcctg ccgctggcct tgctgctcca cgccgccagg 60 ccggaacaga agctgatctc ggaggaggat ctggaggtgc agctggtgga gagcggtggt 120 ggtctcgtgc agcccggcgg tagtctgcgc ctcagctgtg ccgccagcgg tcgcaccttt 180 agcccatatg tgatgggctg gtttcgccaa gcccccggca aaggtcgcga actggtggcc 240 gatattagca gcagcggtgg cagcacctac tacccagata gcgtggaagg ccgcttcacc 300 atcagccgcg ataacgccaa gcgcatggtg tatctgcaga tgaacagtct gcgcgccgag 360 gacaccgccg tgtattattg tgccgccaaa ccatggccac catttggccc atatacctat 420 gcctacaatt actggggcca aggcacccaa gtgaccgtga gcagcggtgg ttctaccacc 480 actcccgcac cccgccctcc tactcctgcc cctaccattg ctagccaacc gcttagtctg 540 agacctgagg cctgtaggcc cgctgctggt ggcgctgtgc acacccgagg attggacttc 600 gcttgcgaca tctacatctg ggcacctctg gctgggacct gcggcgtgtt gttgttgagc 660 ctggtgatta cgctgtactg tagacggggc agacgcagac tcctgtatat attccgccaa 720 ccatttatga gaccagtaca aactactcaa gagaagatg gctgtagctg ccgatttcca 780 gaagaaag aaggaggatg tgaactgaga gtgagattca gcaggagcgc agacgcccc 840 gcgtaccagc agggccagaa ccagctctat aacgagctca atctaggacg aagagaggag 900 tacgatgttt tggaccgcag acgtggccgg gaccctgaga tgggggaag accggagaga 960 aggcgcaacc ctcaggaagg cctgtacaat gaactgcagc gcgatagaat ggcggaggcc 1020 tacagtgaga ttgggatgag aggcgagcgc cggaggggca gagggcacga tggcctttac 1080 cagggtctca gtacagccac ccgcgcacacc tacgacgcccc ttcacatgca ggccctgcct 1140 cctcgc 1146 <210> 23 <211> 1146 <212> DNA <213> Artificial Sequence <400> 23 atggccttac cagtgaccgc cttgctcctg ccgctggcct tgctgctcca cgccgccagg 60 ccggaacaga agctgatctc ggaggaggat ctggaggtgc agctggtgga gagcggtggt 120 ggtctcgtgc agcccggcgg tagtctgcgc ctcagctgtg ccgccagcgg tatcaccttt 180 agcacctata acatgggctg gtttcgccaa gcccccggca aaggtcgcga actggtggcc 240 gccatttccc gcacgggcgg tagcacctac tacccagata gcgtggaagg ccgcttcacc 300 atcagccgcg ataacgccaa gcgcatggtg tatctgcaga tgaacagtct gcgcgccgag 360 gacaccgccg tgtattattg tgccgccagc ctgtatccag atggctatct gagcatctat 420 agctacaatt actggggcca aggcacccaa gtgaccgtga gcagcggtgg ttctaccacc 480 actcccgcac cccgccctcc tactcctgcc cctaccattg ctagccaacc gcttagtctg 540 agacctgagg cctgtaggcc cgctgctggt ggcgctgtgc acacccgagg attggacttc 600 gcttgcgaca tctacatctg ggcacctctg gctgggacct gcggcgtgtt gttgttgagc 660 ctggtgatta cgctgtactg tagacggggc agacgcagac tcctgtatat attccgccaa 720 ccatttatga gaccagtaca aactactcaa gaggaagatg gctgtagctg ccgatttcca 780 gaagaagaag aaggaggatg tgaactgaga gtgagattca gcaggagcgc agacgccccc 840 gcgtaccagc agggccagaa ccagctctat aacgagctca atctaggacg aagagaggag 900 tacgatgttt tggaccgcag acgtggccgg gaccctgaga tggggggaag accgcagaga 960 aggcgcaacc ctcaggaagg cctgtacaat gaactgcagc gcgatagaat ggcggaggcc 1020 tacagtgaga ttgggatgag aggcgagcgc cggaggggca gagggcacga tggcctttac 1080 cagggtctca gtacagccac ccgcgacacc tacgacgccc ttcacatgca ggccctgcct 1140 cctcgc 1146 <210> 24 <211> 20 <212> DNA <213> Artificial Sequence <400> 24 ggagcaggtg atgttgacgg 20 <210> 25 <211> 381 <212> PRT <213> Artificial Sequence <400> 25 Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu 1 5 10 15 His Ala Ala Arg Pro Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu Met 20 25 30 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 35 40 45 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Pro Tyr Ser Ser Tyr 50 55 60 Cys Met Gly Trp Phe Arg Gln Ala Pro Gly Gln Gly Leu Glu Ala Val 65 70 75 80 Ala Ala Ile Asp Ser Asp Gly Arg Thr Arg Tyr Ala Asp Ser Val Lys 85 90 95 Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu 100 105 110 Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala 115 120 125 Ala Arg Phe Gly Pro Met Gly Cys Val Asp Leu Ser Thr Leu Ser Phe 130 135 140 Gly His Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Thr Thr Thr 145 150 155 160 Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro 165 170 175 Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val 180 185 190 His Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro 195 200 205 Leu Ala Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu 210 215 220 Tyr Cys Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro 225 230 235 240 Phe Met Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys 245 250 255 Arg Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu Arg Val Lys Phe 260 265 270 Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu 275 280 285 Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp 290 295 300 Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Gln Arg Arg 305 310 315 320 Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met 325 330 335 Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly 340 345 350 Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp 355 360 365 Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg 370 375 380
Claims
1. A chimeric antigen receptor targeting the CD7 protein, comprising: The extracellular domain, transmembrane domain, and intracellular domain are connected sequentially. The extracellular domain includes an antigen recognition region, which is a nanobody targeting the CD7 protein; the amino acid sequence of the nanobody targeting the CD7 protein is shown in SEQ ID NO: 3; The intracellular domain comprises a co-stimulatory signal transduction region and a CD3ζ intracellular region connected in sequence, forming a co-stimulatory signal transduction region-CD3ζ intracellular region; the amino acid sequence of the co-stimulatory signal transduction region-CD3ζ intracellular region is shown in SEQ ID NO: 6 or SEQ ID NO: 7; The transmembrane structural domain is selected from the transmembrane region of CD8α.
2. The chimeric antigen receptor targeting CD7 protein of claim 1, wherein, The extracellular domain further includes a signal peptide and / or a hinge region; the signal peptide is selected from CD8α signal peptide and / or the hinge region is selected from the hinge region of CD8α.
3. The chimeric antigen receptor targeting the CD7 protein as described in claim 1, characterized in that, The amino acid sequence of the chimeric antigen receptor is shown in SEQ ID NO: 14 or 15.
4. An isolated nucleic acid, characterized in that, The nucleic acid sequence is the nucleic acid sequence encoding the chimeric antigen receptor targeting the CD7 protein as described in any one of claims 1-3.
5. The nucleic acid as described in claim 4, characterized in that, The sequence of the nucleic acid is shown in SEQ ID NO: 20 or 21.
6. A nucleic acid construct comprising the nucleic acid of claim 4 or 5.
7. The nucleic acid construct according to claim 6, characterized in that, The nucleic acid construct is a vector.
8. The nucleic acid construct as described in claim 7, characterized in that, The nucleic acid construct is a lentiviral vector containing a replication initiation site, a 3'LTR, a 5'LTR, and the nucleic acid as described in claim 4 or 5.
9. A lentivirus comprising the nucleic acid construct according to any one of claims 6-8.
10. A method for activating T cells in vitro, the method comprising the step of infecting the T cells with the lentivirus of claim 9.
11. A gene-modified T cell or a pharmaceutical composition containing the gene-modified T cell, characterized in that, The cells contain the nucleic acid as described in claim 4 or 5, or contain the nucleic acid construct as described in any one of claims 6-8, or are infected with the lentivirus as described in claim 9, or are prepared using the method described in claim 10.
12. The use of the chimeric antigen receptor of any one of claims 1-3, the nucleic acid of claim 4 or 5, the nucleic acid construct of any one of claims 6-8, the lentivirus of claim 9, or the genetically modified T cell of claim 11 in any one or more of the following uses: (1) preparing a tumor therapeutic drug; (2) preparing a formulation to improve the killing efficiency against tumors; (3) preparing a formulation to inhibit tumor development; in, The tumor is T-cell type acute lymphoblastic leukemia.
Citation Information
Patent Citations
CD7-CAR-T cell as well as preparation and application thereof
CN110760007A
Pharmaceutical composition containing fusion protein and use thereof
CN112839964A
